Professional Documents
Culture Documents
Networks Functions
Predicted N/A
Physical Interactions
Genetic Interactions
Co-expression
Co-localization
1 of 12
Search parameters
Organism Homo sapiens (human)
Genes DCN , BRCA1 , VCAN , RHOA , NOX4 , PRUNE2 , TGFBR1 , NCF2 , ELK1 ,
CALU , JUND , RAF1 , MDM2 , RAC1 , NDUFB5 , RNF38 , PDK1 , TGFBR2 ,
GREM1
Network Automatically selected weighting method
weighting
Networks A
2 of 12
D
4 of 12
L
5 of 12
S
6 of 12
Z
Zanon-Pichler-2013 , Zeller-Wei-2006 , Zhang-Shang-2006 , Zhang-Vermeulen-2017 ,
Zhang-Wang-2018 , Zhang-Wheeler-2014 , Zhang-Xu-2018 , Zhang-Zou-2011 , Zhao-
Krug-2005 , Zhao-Yang-2011 , Zhong-Vidal-2016 , Zhou-Conrads-2004 , Zhou-
Hanemann-2016 , Zhu-Liu-2018
7 of 12
Genes
Gene Description Rank
RNF38 ring finger protein 38 [Source:HGNC Symbol;Acc:HGNC:18052] N/A
NOX4 NADPH oxidase 4 [Source:HGNC Symbol;Acc:HGNC:7891] N/A
DCN decorin [Source:HGNC Symbol;Acc:HGNC:2705] N/A
GREM1 gremlin 1, DAN family BMP antagonist [Source:HGNC Symbol;Acc: N/A
HGNC:2001]
PRUNE2 prune homolog 2 with BCH domain [Source:HGNC Symbol;Acc:HGNC: N/A
25209]
NDUFB5 NADH:ubiquinone oxidoreductase subunit B5 [Source:HGNC Symbol;Acc: N/A
HGNC:7700]
CALU calumenin [Source:HGNC Symbol;Acc:HGNC:1458] N/A
VCAN versican [Source:HGNC Symbol;Acc:HGNC:2464] N/A
NCF2 neutrophil cytosolic factor 2 [Source:HGNC Symbol;Acc:HGNC:7661] N/A
PDK1 pyruvate dehydrogenase kinase 1 [Source:HGNC Symbol;Acc:HGNC:8809] N/A
JUND JunD proto-oncogene, AP-1 transcription factor subunit [Source:HGNC N/A
Symbol;Acc:HGNC:6206]
ELK1 ETS transcription factor ELK1 [Source:HGNC Symbol;Acc:HGNC:3321] N/A
TGFBR2 transforming growth factor beta receptor 2 [Source:HGNC Symbol;Acc: N/A
HGNC:11773]
MDM2 MDM2 proto-oncogene [Source:HGNC Symbol;Acc:HGNC:6973] N/A
RAC1 Rac family small GTPase 1 [Source:HGNC Symbol;Acc:HGNC:9801] N/A
RHOA ras homolog family member A [Source:HGNC Symbol;Acc:HGNC:667] N/A
TGFBR1 transforming growth factor beta receptor 1 [Source:HGNC Symbol;Acc: N/A
HGNC:11772]
RAF1 Raf-1 proto-oncogene, serine/threonine kinase [Source:HGNC Symbol;Acc: N/A
HGNC:9829]
BRCA1 BRCA1 DNA repair associated [Source:HGNC Symbol;Acc:HGNC:1100] N/A
PARD6A par-6 family cell polarity regulator alpha [Source:HGNC Symbol;Acc: 1
HGNC:15943]
FOS Fos proto-oncogene, AP-1 transcription factor subunit [Source:HGNC 2
Symbol;Acc:HGNC:3796]
PIK3R2 phosphoinositide-3-kinase regulatory subunit 2 [Source:HGNC Symbol;Acc: 3
HGNC:8980]
YWHAG tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein 4
8 of 12
Gene Description Rank
gamma [Source:HGNC Symbol;Acc:HGNC:12852]
STAT6 signal transducer and activator of transcription 6 [Source:HGNC Symbol; 5
Acc:HGNC:11368]
MTBP MDM2 binding protein [Source:HGNC Symbol;Acc:HGNC:7417] 6
MTOR mechanistic target of rapamycin kinase [Source:HGNC Symbol;Acc:HGNC: 7
3942]
PIAS2 protein inhibitor of activated STAT 2 [Source:HGNC Symbol;Acc:HGNC: 8
17311]
KRAS KRAS proto-oncogene, GTPase [Source:HGNC Symbol;Acc:HGNC:6407] 9
HACD3 3-hydroxyacyl-CoA dehydratase 3 [Source:HGNC Symbol;Acc:HGNC: 10
24175]
HIPK1 homeodomain interacting protein kinase 1 [Source:HGNC Symbol;Acc: 11
HGNC:19006]
ACVRL1 activin A receptor like type 1 [Source:HGNC Symbol;Acc:HGNC:175] 12
RPS6KB1 ribosomal protein S6 kinase B1 [Source:HGNC Symbol;Acc:HGNC:10436] 13
PARD3 par-3 family cell polarity regulator [Source:HGNC Symbol;Acc:HGNC: 14
16051]
RASSF5 Ras association domain family member 5 [Source:HGNC Symbol;Acc: 15
HGNC:17609]
CDKN1B cyclin dependent kinase inhibitor 1B [Source:HGNC Symbol;Acc:HGNC: 16
1785]
ENG endoglin [Source:HGNC Symbol;Acc:HGNC:3349] 17
APEX1 apurinic/apyrimidinic endodeoxyribonuclease 1 [Source:HGNC Symbol; 18
Acc:HGNC:587]
XIAP X-linked inhibitor of apoptosis [Source:HGNC Symbol;Acc:HGNC:592] 19
DPYSL2 dihydropyrimidinase like 2 [Source:HGNC Symbol;Acc:HGNC:3014] 20
9 of 12
Networks
Predicted 34.68%
I2D-IntAct-Rat2Human 21.34%
The IntAct molecular interaction database in 2010. Aranda et al (2010). Nucleic Acids Res
Predicted with 1,690 interactions from I2D
I2D-MINT-Mouse2Human 12.52%
MINT: a Molecular INTeraction database. Zanzoni et al (2002). FEBS Lett
Predicted with 1,147 interactions from I2D
I2D-BioGRID-Mouse2Human 0.83%
BioGRID: a general repository for interaction datasets. Stark et al (2006). Nucleic Acids Res
Predicted with 10,524 interactions from I2D
IREF-bind 5.89%
Physical Interactions with 3,524 interactions from iRefIndex
So-Colwill-2015 5.79%
Integrative analysis of kinase networks in TRAIL-induced apoptosis provides a source of potential targets for combination
therapy. So et al (2015). Sci Signal
Physical Interactions with 652 interactions from BioGRID
Lim-Zoghbi-2006 5.58%
A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration. Lim et al (2006).
Cell
Physical Interactions with 5,393 interactions from iRefIndex
Woods-Monteiro-2012 B 4.97%
Charting the landscape of tandem BRCT domain-mediated protein interactions. Woods et al (2012). Sci Signal
Physical Interactions with 325 interactions from BioGRID
Barrios-Rodiles-Wrana-2005 1.82%
High-throughput mapping of a dynamic signaling network in mammalian cells. Barrios-Rodiles et al (2005). Science
Physical Interactions with 596 interactions from iRefIndex
Hein-Mann-2015 0.85%
A human interactome in three quantitative dimensions organized by stoichiometries and abundances. Hein et al (2015). Cell
Physical Interactions with 27,015 interactions from BioGRID
IREF-bind-translation 0.73%
Physical Interactions with 6,056 interactions from iRefIndex
Rual-Vidal-2005 0.64%
Towards a proteome-scale map of the human protein-protein interaction network. Rual et al (2005). Nature
Physical Interactions with 4,031 interactions from iRefIndex
Kennedy-Kolch-2020 A 0.51%
Extensive rewiring of the EGFR network in colorectal cancer cells expressing transforming levels of KRAS<sup>G13D</sup>.
10 of 12
Physical Interactions 27.29%
Kennedy-Kolch-2020 A
Kennedy et al (2020). Nat Commun
Physical Interactions with 4,232 interactions from BioGRID
Miyamoto-Sato-Yanagawa-2010 0.36%
A comprehensive resource of interacting protein regions for refining human transcription factor networks. Miyamoto-Sato et al
(2010). PLoS One
Physical Interactions with 934 interactions from iRefIndex
Vastrik-Stein-2007 0.07%
Reactome: a knowledge base of biologic pathways and processes. Vastrik et al (2007). Genome Biol
Physical Interactions with 111,926 interactions from iRefIndex
IREF-reactome 0.07%
Physical Interactions with 111,926 interactions from iRefIndex
IREF-SMALL-SCALE-STUDIES 10.15%
Genetic Interactions with 1,159 interactions from iRefIndex
BIOGRID-SMALL-SCALE-STUDIES 7.43%
Genetic Interactions with 651 interactions from BioGRID
Co-expression 17.47%
Rosenwald-Staudt-2001 2.89%
Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. Rosenwald
et al (2001). J Exp Med
Co-expression with 118,097 interactions from supplementary material
Ramaswamy-Golub-2001 2.67%
Multiclass cancer diagnosis using tumor gene expression signatures. Ramaswamy et al (2001). Proc Natl Acad Sci U S A
Co-expression with 284,829 interactions from supplementary material
Mallon-McKay-2013 2.55%
StemCellDB: the human pluripotent stem cell database at the National Institutes of Health. Mallon et al (2013). Stem Cell Res
Co-expression with 602,113 interactions from GEO
Arijs-Rutgeerts-2009 2.50%
Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment. Arijs
et al (2009). PLoS One
Co-expression with 676,695 interactions from GEO
Wang-Cheung-2015 1.96%
Genetic variation in insulin-induced kinase signaling. Wang et al (2015). Mol Syst Biol
Co-expression with 422,896 interactions from GEO
Wu-Garvey-2007 1.40%
The effect of insulin on expression of genes and biochemical pathways in human skeletal muscle. Wu et al (2007). Endocrine
Co-expression with 275,155 interactions from GEO
Rieger-Chu-2004 1.00%
11 of 12
Co-expression 17.47%
Rieger-Chu-2004
Toxicity from radiation therapy associated with abnormal transcriptional responses to DNA damage. Rieger et al (2004). Proc
Natl Acad Sci U S A
Co-expression with 266,879 interactions from GEO
Burington-Shaughnessy-2008 1.00%
Tumor cell gene expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to
survival in multiple myeloma. Burington et al (2008). Clin Cancer Res
Co-expression with 295,320 interactions from GEO
Alizadeh-Staudt-2000 0.99%
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Alizadeh et al (2000). Nature
Co-expression with 92,360 interactions from supplementary material
Wang-Maris-2006 0.34%
Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional
alterations in DNA copy number. Wang et al (2006). Cancer Res
Co-expression with 270,388 interactions from GEO
Innocenti-Brown-2011 0.15%
Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue.
Innocenti et al (2011). PLoS Genet
Co-expression with 620,205 interactions from GEO
Perou-Botstein-2000 0.03%
Molecular portraits of human breast tumours. Perou et al (2000). Nature
Co-expression with 189,373 interactions from supplementary material
INTERPRO 2.29%
Shared protein domains with 621,159 interactions from InterPro
Co-localization 0.69%
Johnson-Shoemaker-2003 0.69%
Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Johnson et al (2003). Science
Co-localization with 426,464 interactions from GEO
12 of 12